Treatment of extrapyramidal side effects with terguride.
Terguride, a partial dopamine agonist, was administered in a 4-week open clinical trial to 17 schizophrenic patients suffering from extrapyramidal side effects of neuroleptic treatment. The neuroleptic dosage was kept constant. The mean final daily dose of terguride reached 3.4 mg (SD = 2.0). Fourteen patients completed the trial. Total scores on the Rating Scale for Extrapyramidal Side Effects and the Brief Psychiatric Rating Scale showed a significant improvement of 69% and 40%, respectively. There was also a significant improvement in all BPRS factor scores.
Filip
V
V
Prague Psychiatric Center, Czechoslovakia.
Marsálek
M
M
Hálková
E
E
Karen
P
P
D000284:Administration, Oral; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015259:Dopamine Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004409:Dyskinesia, Drug-Induced / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008090:Lisuride / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000175:diagnosis; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000523:psychology; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D014150:Antipsychotic Agents; D015259:Dopamine Agents; C006208:dironyl; D008090:Lisuride